Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better?

Jordi Remon¹, Benjamin Besse^{2

3}

Affiliations

¹ Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
² Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Benjamin.BESSE@gustaveroussy.fr.
³ Université Paris-Saclay, Orsay, France. Benjamin.BESSE@gustaveroussy.fr.

Comment

Jordi Remon et al. Nat Rev Clin Oncol. 2022 Jan.

. 2022 Jan;19(1):7-8.

doi: 10.1038/s41571-021-00574-1.

Jordi Remon¹, Benjamin Besse^{2

3}

¹ Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
² Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Benjamin.BESSE@gustaveroussy.fr.
³ Université Paris-Saclay, Orsay, France. Benjamin.BESSE@gustaveroussy.fr.

No abstract available

Comment on

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Felip E, et al. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20. Lancet. 2021. PMID: 34555333 Clinical Trial.

1. Wu, Y.-L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020). - DOI
1. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375, 1267–1277 (2010). - DOI
1. Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50. J. Clin. Oncol. 39, 2339–2349 (2021). - DOI
1. Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021). - DOI
1. Eggermont, A. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 643–654 (2021). - DOI